Literature DB >> 2466751

A cytokeratin immunohistochemical study of alcoholic liver disease: evidence that hepatocytes can express 'bile duct-type' cytokeratins.

P Van Eyken1, R Sciot, V J Desmet.   

Abstract

A cytokeratin immunohistochemical study was performed on 40 liver biopsies diagnosed as alcoholic liver disease to further investigate the cytoskeletal changes occurring in this disease. On paraffin sections of 29 cases, a variable number of hepatocytes were reactive with a polyclonal antiserum that normally stains only bile ducts. Using monoclonal antibodies specific for a single cytokeratin polypeptide on cryostat sections, a variable number of hepatocytes were immunoreactive for cytokeratin no. 7 in 23 cases and also for cytokeratin no. 19 in seven cases. Both these polypeptides are restricted to bile duct cells in the normal liver. The number of hepatocytes positive for bile duct-type cytokeratins increased and their location changed with the severity of the disease. Mallory bodies were reactive with monoclonal antibodies CAM 5.2 and anti-cytokeratin no. 18 but unreactive with anti-cytokeratin no. 8. except in one case. In two cases, Mallory bodies reactive with both monoclonal antibodies anti-cytokeratin no. 7 and anti-cytokeratin no. 19 were found. These results clearly indicate that hepatocytes in alcoholic liver disease can express immunoreactivity for bile duct-type cytokeratins. Our data also demonstrate heterogeneity in the composition of Mallory bodies. Whether hepatocytes expressing bile duct-type cytokeratins are the precursors of Mallory body-containing cells is not clear at present.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2466751     DOI: 10.1111/j.1365-2559.1988.tb02092.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  11 in total

Review 1.  Expression kinetics of hepatic progenitor markers in cellular models of human liver development recapitulating hepatocyte and biliary cell fate commitment.

Authors:  Pooja Chaudhari; Lipeng Tian; Abhijeet Deshmukh; Yoon-Young Jang
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-06

2.  Liver stem cells.

Authors:  Neil D Theise
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

3.  Glutathione S-transferases in alcoholic liver disease.

Authors:  D J Harrison; L May; P C Hayes; M M Haque; J D Hayes
Journal:  Gut       Date:  1990-08       Impact factor: 23.059

Review 4.  Wound healing in the liver with particular reference to stem cells.

Authors:  M Alison; M Golding; C Sarraf
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1998-06-29       Impact factor: 6.237

5.  Growth and differentiation in culture of clonogenic hepatocytes that express both phenotypes of hepatocytes and biliary epithelial cells.

Authors:  C Tateno; K Yoshizato
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

6.  Vimentin expression of newly formed rat bile duct epithelial cells in secondary biliary fibrosis.

Authors:  S Milani; H Herbst; D Schuppan; G Niedobitek; K Y Kim; H Stein
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

7.  Patterns of cytokeratin expression by neoplastic and non-neoplastic epithelium.

Authors:  G Mortimer; D N Jones; H Assaf; T al-Ahmadi
Journal:  Ir J Med Sci       Date:  1993-03       Impact factor: 1.568

8.  Alcoholic liver disease. Parenchyma to stroma relationship in fibrosis and cirrhosis as revealed by three-dimensional reconstruction and immunohistochemistry.

Authors:  H P Dinges; K Zatloukal; H Denk; J Smolle; S Mair
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

Review 9.  Toward unraveling the complexity of simple epithelial keratins in human disease.

Authors:  M Bishr Omary; Nam-On Ku; Pavel Strnad; Shinichiro Hanada
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

Review 10.  Diagnosis of alcoholic liver disease.

Authors:  Cara Torruellas; Samuel W French; Valentina Medici
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.